ONXEO
Onxeo is a biotechnology company that develops drugs for oncology. It offers Beleodaq, a histone deactylase inhibitor for the treatment of peripheral T-cell lymphoma; Livatag, a nanoparticle formulation of doxorubicin, which is in Phase III clinical trials for the treatment of primary liver cancer; Validive, a mucoadhesive buccal tablet that is in Phase II clinical trials for the prevention and the treatment of chemoradioation therapy-induced severe oral mucositis in patients with head and neck cancer; and Combo BelCHOP, which is Phase II clinical trials for the treatment of peripheral T-cell lymphoma. Onxeo is headquartered in Paris, France.
ONXEO
Industry:
Biopharma Biotechnology Pharmaceutical
Founded:
1997-01-01
Address:
Paris, Ile-de-France, France
Country:
France
Website Url:
http://www.onxeo.com
Total Employee:
11+
Status:
Active
Contact:
+330145587600
Email Addresses:
[email protected]
Total Funding:
60.4 M EUR
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible SPF SSL By Default Google Analytics LetsEncrypt Apple Mobile Web Clips Icon WordPress Content Delivery Network Google Universal Analytics
Similar Organizations
Alix
Alix SA is a biotechnology company that develops drugs for the identification of therapeutic targets.
Aura Biosciences
Aura Biosciences is a biotechnology company that focuses on the development of drugs by using tumor targeted pseudovirions.
Axcella
Axcella is a biotechnology company providing therapeutics development solutions.
Immutep
Immutep is a biopharmaceutical company developing immunotherapeutics in oncology.
Prestizia
Prestizia is a biotechnology company that is developing a microRNA1 technology.
Reata Pharmaceuticals
Reata Pharmaceuticals is a biopharmaceutical company that develops drugs for cancer, inflammation, and neurodegenerative diseases.
Current Advisors List
Current Employees Featured
Founder
Stock Details
Acquisitions List
| Date | Company | Article | Price |
|---|---|---|---|
| 2016-02-29 | DNA Therapeutics | DNA Therapeutics acquired by Onxeo | 1.85 M USD |
| 2007-06-27 | TopoTarget Switzerland | TopoTarget Switzerland acquired by Onxeo | N/A |
| 2002-06-04 | TopoTarget UK Limited | TopoTarget UK Limited acquired by Onxeo | N/A |
Investors List
Invus
Invus investment in Post-IPO Equity - Onxeo
Financière de la Montagne
Financière de la Montagne investment in Post-IPO Equity - Onxeo
Bpifrance
Bpifrance investment in Post-IPO Equity - Onxeo
Oséo
Oséo investment in Grant - Onxeo
Key Employee Changes
| Date | New article |
|---|---|
| 2022-04-07 | Onxeo Appoints Dr. Shefali Agarwal as President and Chief Executive Officer |
| 2022-01-03 | Onxeo Appoints Julien Miara as New Interim CEO |
Official Site Inspections
http://www.onxeo.com Semrush global rank: 5.13 M Semrush visits lastest month: 1.59 K
- Host name: aec037177372cc6cd.awsglobalaccelerator.com
- IP address: 3.33.251.168
- Location: Seattle United States
- Latitude: 47.6348
- Longitude: -122.3451
- Metro Code: 819
- Timezone: America/Los_Angeles
- Postal: 98109
